Achieve Life Sciences targets NDA submission for cytisinicline in June 2025 as open label study hits key milestones
Source: SeekingAlpha
2025-05-13 12:16:42 ET
More on Achieve Life Sciences
- Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript
- Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Achieve Life Sciences
- Historical earnings data for Achieve Life Sciences
- Financial information for Achieve Life Sciences
Read the full article on Seeking Alpha
For further details see:
Achieve Life Sciences targets NDA submission for cytisinicline in June 2025 as open label study hits key milestones
Achieve Life Sciences Inc.
NASDAQ: ACHV
ACHV Trading
0.73% G/L:
$5.409 Last:
1,030,133 Volume:
$5.10 Open:
ACHV Latest News
June 02, 2026 08:30:00 am
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
May 19, 2026 02:15:00 pm
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
ACHV Stock Data
$234,761,887
51,636,968
N/A
28
N/A
Biotechnology & Life Sciences
Healthcare
CA
Bothell
